These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24652679)

  • 61. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.
    Trinh J; Amouri R; Duda JE; Morley JF; Read M; Donald A; Vilariño-Güell C; Thompson C; Szu Tu C; Gustavsson EK; Ben Sassi S; Hentati E; Zouari M; Farhat E; Nabli F; Hentati F; Farrer MJ
    Neurobiol Aging; 2014 May; 35(5):1125-31. PubMed ID: 24355527
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice.
    Feng YK; Wu QL; Peng YW; Liang FY; You HJ; Feng YW; Li G; Li XJ; Liu SH; Li YC; Zhang Y; Pei Z
    J Neuroinflammation; 2020 Nov; 17(1):347. PubMed ID: 33213462
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.
    Xu E; Boddu R; Abdelmotilib HA; Sokratian A; Kelly K; Liu Z; Bryant N; Chandra S; Carlisle SM; Lefkowitz EJ; Harms AS; Benveniste EN; Yacoubian TA; Volpicelli-Daley LA; Standaert DG; West AB
    Mol Neurodegener; 2022 Jan; 17(1):7. PubMed ID: 35012605
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
    Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
    J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
    Podlesniy P; Vilas D; Taylor P; Shaw LM; Tolosa E; Trullas R
    Neurobiol Dis; 2016 Oct; 94():10-7. PubMed ID: 27260835
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 71. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
    Ho DH; Seol W; Eun JH; Son IH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An emerging role for LRRK2 in the immune system.
    Dzamko N; Halliday GM
    Biochem Soc Trans; 2012 Oct; 40(5):1134-9. PubMed ID: 22988878
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide.
    Kim J; Jeong YH; Lee EJ; Park JS; Seo H; Kim HS
    Biochem Biophys Res Commun; 2017 Nov; 493(2):879-886. PubMed ID: 28958936
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2.
    Tong Y; Shen J
    Biochem Soc Trans; 2012 Oct; 40(5):1042-6. PubMed ID: 22988862
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
    Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
    Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.
    Hakimi M; Selvanantham T; Swinton E; Padmore RF; Tong Y; Kabbach G; Venderova K; Girardin SE; Bulman DE; Scherzer CR; LaVoie MJ; Gris D; Park DS; Angel JB; Shen J; Philpott DJ; Schlossmacher MG
    J Neural Transm (Vienna); 2011 May; 118(5):795-808. PubMed ID: 21552986
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.
    Wang L; Xie C; Greggio E; Parisiadou L; Shim H; Sun L; Chandran J; Lin X; Lai C; Yang WJ; Moore DJ; Dawson TM; Dawson VL; Chiosis G; Cookson MR; Cai H
    J Neurosci; 2008 Mar; 28(13):3384-91. PubMed ID: 18367605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.